Macrogenics Inc income statement

In fiscal 2025, Macrogenics Inc reported revenue of $150m, down 0.3% on the year before, operating income of −$72.8m (a -48.7% margin) and net income of −$74.6m, or −$1.18 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Macrogenics Inc: income statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	57	64	58	48	101	92	158	60	64	105	77	152	59	150	150	168
Cost of revenue	—	—	—	—	—	—	—	—	0	0	3	3	1	1	0	—
Gross profit	—	—	—	—	—	—	—	—	64	105	75	149	58	149	150	—
Research and development	41	45	47	70	98	122	147	191	195	193	215	207	167	177	147	140
General and administrative	11	10	11	16	23	30	33	41	46	43	63	59	52	71	39	37
Operating income	5	8	0	−38	−20	−60	−22	−171	−177	−131	−203	−121	−168	−111	−73	−41
Interest expense	—	—	—	—	—	—	—	—	—	—	0	0	1	1	9	17
Income before tax	—	—	—	—	—	—	—	—	—	—	—	−120	−9	−66	−75	—
Income tax	—	0	0	0	0	0	0	0	0	0	0	0	0	1	−1	—
Net income	7	8	−0	−38	−20	−59	−20	−171	−152	−130	−202	−120	−9	−67	−75	−15
Diluted EPS	$0.00	$0.00	−$0.01	−$1.40	−$0.63	−$1.69	−$0.54	—	—	−$2.47	−$3.37	−$1.95	−$0.15	−$1.07	−$1.18	−$0.23
Diluted shares (average)	4m	4m	27m	27m	32m	35m	36m	41m	48m	52m	60m	61m	62m	63m	63m	63m
EBITDA	6	9	2	−36	−17	−52	−15	−162	−165	−119	−192	−110	−159	−103	−66	−35

US$ millions unless shown otherwise. Fiscal quarters.

Macrogenics Inc: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	111	19	13	7	73	41	21	33
Cost of revenue	0	0	0	0	0	0	—	—
Gross profit	111	19	13	7	73	41	—	—
Research and development	41	39	40	41	33	34	35	39
General and administrative	14	28	11	9	10	9	10	8
Operating income	54	−53	−43	−43	19	−12	−33	−14
Interest expense	0	−0	0	1	3	4	5	4
Income before tax	56	−14	—	−43	17	−15	—	−70
Income tax	0	1	—	0	0	−1	—	0
Net income	56	−15	−41	−36	17	−14	−37	20
Diluted EPS	$0.90	−$0.25	−$0.65	−$0.57	$0.27	−$0.22	−$0.58	$0.31
EBITDA	56	−51	−41	−41	20	−10	−32	−13

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IBRX vs MGNX MGNX vs NUVB BEAM vs MGNX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Macrogenics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Macrogenics Inc.